## List of Figures

<table>
<thead>
<tr>
<th>Figure no.</th>
<th>Contents</th>
<th>Pg.No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Schematically overview of pathways involved in lipoprotein metabolism</td>
<td>7</td>
</tr>
<tr>
<td>1.2</td>
<td>Pathogenesis of atherosclerosis</td>
<td>10</td>
</tr>
<tr>
<td>1.3</td>
<td>Approaches to Increase solubility/ Dissolution</td>
<td>15</td>
</tr>
<tr>
<td>1.4</td>
<td>Simple eutectic mixtures</td>
<td>30</td>
</tr>
<tr>
<td>1.5</td>
<td>Discontinuous Solid Solutions – Exist at extremes of composition</td>
<td>31</td>
</tr>
<tr>
<td>1.6</td>
<td>Continuous Solid Solution Two solids miscible in solid state in all proportions</td>
<td>31</td>
</tr>
<tr>
<td>1.7</td>
<td>Glass solutions and suspensions</td>
<td>31</td>
</tr>
<tr>
<td>1.8</td>
<td>Chemical structure and schematic drawing of β-cyclodextrin</td>
<td>36</td>
</tr>
<tr>
<td>1.9</td>
<td>Various types of phase solubility curves</td>
<td>41</td>
</tr>
<tr>
<td>1.10</td>
<td>Structure of β-cyclodextrin</td>
<td>54</td>
</tr>
<tr>
<td>5.1</td>
<td>FTIR spectrum of Atorvastatin</td>
<td>103</td>
</tr>
<tr>
<td>5.2</td>
<td>FTIR spectrum of Fenofibrate</td>
<td>104</td>
</tr>
<tr>
<td>5.3</td>
<td>FTIR spectrum of Ezetimibe</td>
<td>105</td>
</tr>
<tr>
<td>5.4</td>
<td>Atorvastatin differential scanning calorimetry</td>
<td>106</td>
</tr>
<tr>
<td>5.5</td>
<td>Fenofibrate differential scanning calorimetry</td>
<td>106</td>
</tr>
<tr>
<td>5.6</td>
<td>Ezetimibe differential scanning calorimetry</td>
<td>107</td>
</tr>
<tr>
<td>5.7</td>
<td>X-ray diffraction spectra of Atorvastatin</td>
<td>107</td>
</tr>
<tr>
<td>5.8</td>
<td>X-ray diffraction spectra of Fenofibrate</td>
<td>108</td>
</tr>
<tr>
<td>5.9</td>
<td>X-ray diffraction spectra of Ezetimibe</td>
<td>108</td>
</tr>
<tr>
<td>5.10</td>
<td>Photomicrograph of Atorvastatin</td>
<td>109</td>
</tr>
<tr>
<td>5.11</td>
<td>Photomicrograph of Fenofibrate</td>
<td>109</td>
</tr>
<tr>
<td>5.12</td>
<td>Photomicrograph of Ezetimibe</td>
<td>109</td>
</tr>
<tr>
<td>5.13</td>
<td>Representative chromatogram obtained for standard solution</td>
<td>111</td>
</tr>
</tbody>
</table>
## LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.14</td>
<td>Calibration curve of Atorvastatin</td>
<td>114</td>
</tr>
<tr>
<td>5.15</td>
<td>Calibration curve of Fenofibrate</td>
<td>115</td>
</tr>
<tr>
<td>5.16</td>
<td>Calibration curve of Ezetimibe</td>
<td>116</td>
</tr>
<tr>
<td>5.17</td>
<td>Photo degradation of AFE</td>
<td>117</td>
</tr>
<tr>
<td>5.18</td>
<td>Thermal degradation of AFE</td>
<td>118</td>
</tr>
<tr>
<td>5.19</td>
<td>Acid degradation of AFE</td>
<td>118</td>
</tr>
<tr>
<td>5.20</td>
<td>Alkali degradation of AFE</td>
<td>118</td>
</tr>
<tr>
<td>5.21</td>
<td>Oxidative degradation of AFE</td>
<td>119</td>
</tr>
<tr>
<td>5.22</td>
<td>FTIR spectrum of AT, FE and EZ</td>
<td>121</td>
</tr>
<tr>
<td>5.23</td>
<td>DSC thermograph of AT and FE</td>
<td>122</td>
</tr>
<tr>
<td>5.24</td>
<td>DSC thermograph of AT and EZ</td>
<td>122</td>
</tr>
<tr>
<td>5.25</td>
<td>DSC thermograph of FE and EZ</td>
<td>123</td>
</tr>
<tr>
<td>5.26</td>
<td>DSC thermograph of AT, FE and EZ ratio 1 : 1 : 1</td>
<td>123</td>
</tr>
<tr>
<td>5.27</td>
<td>DSC thermograph of AT, FE and EZ ratio 1 : 16 : 1</td>
<td>124</td>
</tr>
<tr>
<td>5.28</td>
<td>X-ray diffraction spectra of AFE</td>
<td>125</td>
</tr>
<tr>
<td>5.29.1</td>
<td>Solubility study of AFE with PVP</td>
<td>128</td>
</tr>
<tr>
<td>5.29.2</td>
<td>Solubility study of AFE with Trehalose</td>
<td>128</td>
</tr>
<tr>
<td>5.29.3</td>
<td>Solubility study of AFE with Anhydrous Citric acid</td>
<td>129</td>
</tr>
<tr>
<td>5.29.4</td>
<td>Solubility study of AFE with Urea</td>
<td>129</td>
</tr>
<tr>
<td>5.29.5</td>
<td>Solubility study of AFE with Mannitol</td>
<td>129</td>
</tr>
<tr>
<td>5.29.6</td>
<td>Solubility study of AFE with Sucrose</td>
<td>130</td>
</tr>
<tr>
<td>5.29.7</td>
<td>Solubility study of AFE with Raffinose</td>
<td>130</td>
</tr>
<tr>
<td>5.30</td>
<td>FTIR spectrum of PEG 6000</td>
<td>133</td>
</tr>
<tr>
<td>5.31</td>
<td>FTIR spectrum of PMPC</td>
<td>134</td>
</tr>
<tr>
<td>5.32</td>
<td>DSC thermograph of PEG 6000</td>
<td>135</td>
</tr>
<tr>
<td>5.33</td>
<td>DSC thermograph of PMPC</td>
<td>135</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>Page</td>
</tr>
<tr>
<td>--------</td>
<td>-------------</td>
<td>------</td>
</tr>
<tr>
<td>5.34</td>
<td>X-ray diffraction spectra of PEG 6000</td>
<td>136</td>
</tr>
<tr>
<td>5.35</td>
<td>X-ray diffraction spectra of PMPC</td>
<td>136</td>
</tr>
<tr>
<td>5.36</td>
<td>Photomicrograph of PEG 6000</td>
<td>137</td>
</tr>
<tr>
<td>5.37</td>
<td>Photomicrograph of PMPC</td>
<td>137</td>
</tr>
<tr>
<td>5.38</td>
<td>Cumulative % drug release vs time of AT (SE method Separate)</td>
<td>140</td>
</tr>
<tr>
<td>5.39</td>
<td>Cumulative % drug release vs time of AT (Melt method Separate)</td>
<td>140</td>
</tr>
<tr>
<td>5.40</td>
<td>Cumulative % drug release vs time of AT (SE method Combination)</td>
<td>141</td>
</tr>
<tr>
<td>5.41</td>
<td>Cumulative % drug release vs time of AT (Melt method Combination)</td>
<td>141</td>
</tr>
<tr>
<td>5.42</td>
<td>Cumulative % drug release vs time of FE (SE method Separate)</td>
<td>142</td>
</tr>
<tr>
<td>5.43</td>
<td>Cumulative % drug release vs time of FE (Melt method Separate)</td>
<td>142</td>
</tr>
<tr>
<td>5.44</td>
<td>Cumulative % drug release vs time of FE (SE method Combination)</td>
<td>143</td>
</tr>
<tr>
<td>5.45</td>
<td>Cumulative % drug release vs time of FE (Melt method Combination)</td>
<td>143</td>
</tr>
<tr>
<td>5.46</td>
<td>Cumulative % drug release vs time of EZ (SE method Separate)</td>
<td>144</td>
</tr>
<tr>
<td>5.47</td>
<td>Cumulative % drug release vs time of EZ (Melt method Separate)</td>
<td>144</td>
</tr>
<tr>
<td>5.48</td>
<td>Cumulative % drug release vs time of EZ (SE method Combination)</td>
<td>145</td>
</tr>
<tr>
<td>5.49</td>
<td>Cumulative % drug release vs time of EZ (Melt method Combination)</td>
<td>145</td>
</tr>
<tr>
<td>5.50</td>
<td>DSC thermograph of SEPC-3</td>
<td>149</td>
</tr>
<tr>
<td>5.51</td>
<td>DSC thermograph of MPC-3</td>
<td>149</td>
</tr>
<tr>
<td>5.52</td>
<td>X-ray diffraction spectra of MPC-3</td>
<td>150</td>
</tr>
<tr>
<td>5.53</td>
<td>X-ray diffraction spectra of SEPC-3</td>
<td>150</td>
</tr>
<tr>
<td>5.54</td>
<td>Photomicrograph of MPC</td>
<td>151</td>
</tr>
<tr>
<td>5.55</td>
<td>Photomicrograph of SEPC</td>
<td>151</td>
</tr>
<tr>
<td>5.56.1</td>
<td>Phase solubility curve of AT and β-CD</td>
<td>152</td>
</tr>
<tr>
<td>5.56.2</td>
<td>Phase solubility curve of FE and β-CD</td>
<td>152</td>
</tr>
<tr>
<td>5.56.3</td>
<td>Phase solubility curve of EZ and β-CD</td>
<td>152</td>
</tr>
<tr>
<td>5.57</td>
<td>FTIR spectra of β-CD</td>
<td>154</td>
</tr>
<tr>
<td>5.58</td>
<td>FTIR spectra of PMBC</td>
<td>154</td>
</tr>
<tr>
<td>5.59</td>
<td>DSC thermograph of β-CD</td>
<td>155</td>
</tr>
<tr>
<td>Figure No.</td>
<td>Description</td>
<td>Page</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>5.60</td>
<td>DSC thermograph of PMBC</td>
<td>156</td>
</tr>
<tr>
<td>5.61</td>
<td>X-ray diffraction spectra of β-CD</td>
<td>156</td>
</tr>
<tr>
<td>5.62</td>
<td>X-ray diffraction spectra of PMBC</td>
<td>157</td>
</tr>
<tr>
<td>5.63</td>
<td>Photomicrograph of β-CD</td>
<td>157</td>
</tr>
<tr>
<td>5.64</td>
<td>Photomicrograph of PMBC</td>
<td>157</td>
</tr>
<tr>
<td>5.65</td>
<td>Cumulative % drug release vs time of AT (Inclusion Complex Separate)</td>
<td>161</td>
</tr>
<tr>
<td>5.66</td>
<td>Cumulative % drug release vs time of AT (Inclusion Complex Combination)</td>
<td>161</td>
</tr>
<tr>
<td>5.67</td>
<td>Cumulative % drug release vs time of FE (Inclusion Complex Separate)</td>
<td>162</td>
</tr>
<tr>
<td>5.68</td>
<td>Cumulative % drug release vs time of FE (Inclusion Complex Combination)</td>
<td>162</td>
</tr>
<tr>
<td>5.69</td>
<td>Cumulative % drug release vs time of EZ (Inclusion Complex Separate)</td>
<td>163</td>
</tr>
<tr>
<td>5.70</td>
<td>Cumulative % drug release vs time of EZ (Inclusion Complex Combination)</td>
<td>163</td>
</tr>
<tr>
<td>5.71</td>
<td>DSC thermograph of KNBC</td>
<td>167</td>
</tr>
<tr>
<td>5.72</td>
<td>DSC thermograph of CEBC</td>
<td>167</td>
</tr>
<tr>
<td>5.73</td>
<td>X-ray diffraction spectra of KNBC</td>
<td>168</td>
</tr>
<tr>
<td>5.74</td>
<td>X-ray diffraction spectra of CEBC</td>
<td>168</td>
</tr>
<tr>
<td>5.75</td>
<td>Photomicrograph of KNBC</td>
<td>169</td>
</tr>
<tr>
<td>5.76</td>
<td>Photomicrograph of CEBC</td>
<td>169</td>
</tr>
<tr>
<td>5.77</td>
<td>Counter plot and response surface plot showing the effect of polymer ratio (A) and Concentration of Disintegrant (B) on response Y1 and Y2 in melt method</td>
<td>184</td>
</tr>
<tr>
<td>5.78</td>
<td>Counter plot and response surface plot showing the effect of polymer ratio (A) and Concentration of Disintegrant (B) on response Y1 and Y2 in Solvent Evaporation method</td>
<td>185</td>
</tr>
<tr>
<td>5.79</td>
<td>Counter plot and response surface plot showing the effect of polymer ratio (A) and Concentration of Disintegrant (B) on response Y1 and Y2</td>
<td>186</td>
</tr>
<tr>
<td>Figure</td>
<td>Description</td>
<td>Page</td>
</tr>
<tr>
<td>--------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>5.80</td>
<td>Counter plot and response surface plot showing the effect of polymer ratio (A) and Concentration of Disintegrant (B) on response Y1 and Y2 in Co-Evaporation method</td>
<td>187</td>
</tr>
<tr>
<td>5.81</td>
<td>Comparison of AT release profile of CEBC and market</td>
<td>191</td>
</tr>
<tr>
<td>5.82</td>
<td>Comparison of FE release profile of CEBC and market</td>
<td>192</td>
</tr>
<tr>
<td>5.83</td>
<td>Comparison of EZ release profile of CEBC and market</td>
<td>192</td>
</tr>
<tr>
<td>5.84</td>
<td>Comparison of mean plasma concentration vs time of AT from CEBC and market</td>
<td>194</td>
</tr>
<tr>
<td>5.85</td>
<td>Comparison of mean plasma concentration vs time of FE from CEBC and market</td>
<td>194</td>
</tr>
<tr>
<td>5.86</td>
<td>Comparison of mean plasma concentration vs time of Ez from CEBC and market</td>
<td>195</td>
</tr>
<tr>
<td>5.87</td>
<td>FRA/FRD and IVIVC of AT of CEBC</td>
<td>197</td>
</tr>
<tr>
<td>5.88</td>
<td>FRA/FRD and IVIVC of FE of CEBC</td>
<td>197</td>
</tr>
<tr>
<td>5.89</td>
<td>FRA/FRD and IVIVC of EZ of CEBC</td>
<td>197</td>
</tr>
<tr>
<td>5.90</td>
<td>Release profile of AT in half dose</td>
<td>199</td>
</tr>
<tr>
<td>5.91</td>
<td>Release profile of FE in half dose</td>
<td>199</td>
</tr>
<tr>
<td>5.92</td>
<td>Release profile of EZ in half dose</td>
<td>199</td>
</tr>
</tbody>
</table>